Likewise, miR-141 was downregulated in breast cancer, and overexpression of miR-141 was associated with clinicopathologic features, such as decreased expressions of proliferation-related factors Ki67, human epidermal growth factor receptor 2 (HER2), and PCNA.20 Here, ERBB2 is linked to breast carcinoma.